Sponsors
The bill narrows orphan-drug exclusivity to indication-specific protections, improving near-term patient and hospital access to alternative treatments while reducing revenue protections that could weaken incentives to develop some future rare-disease therapies.
Patients with rare diseases and hospitals/health systems gain earlier access to alternative or additional FDA-approved treatments because orphan-drug exclusivity is limited to specific approved uses rather than broad protections across a rare disease.
Manufacturers of orphan-designated drugs may receive reduced market exclusivity for follow-on products or broader claims, lowering expected revenues for sponsors of these drugs.
Reduced or narrower exclusivity could discourage investment in development of therapies for less-common indications within a rare disease, potentially slowing the long-term pipeline of new treatments for patients.
Based on analysis of 2 sections of legislative text.
Narrows orphan-drug exclusivity to the specific approved use or indication within a rare disease, defines that term, and applies it to all designated drugs regardless of dates.
Introduced January 28, 2026 by Tammy Baldwin · Last progress January 28, 2026
Limits the scope of orphan-drug marketing exclusivity so exclusivity and related exceptions apply only to the specific approved use or indication within a rare disease or condition, rather than to the broader disease or condition. It also defines "approved use or indication" and makes the change apply to any drug with an existing orphan designation regardless of when it was designated, approved, or licensed.